VJOncoAlert Journal Club | End points for the next-generation bladder-sparing perioperative trials for patients with MIBC

Andrea Necchi • 26 Sep 2025

In this latest episode of the VJOncoAlert Journal Club, Andrea Necchi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses consensus recommendations from the International Bladder Cancer Group and Global Society of Rare Genitourinary Tumors on designing perioperative trials for muscle-invasive bladder cancer (MIBC) with a focus on bladder preservation. The panel outlined standardized definitions of clinical complete response and emphasized event-free survival as the preferred primary endpoint to assess durability of benefit. The framework also highlights the importance of risk-adapted approaches and patient-centered decision-making in future bladder-sparing strategies.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.